Boehringer Ingelheim and Microsoft Collaborate on AI Research

German pharma firm partners with tech giant on artificial intelligence projects.

The partnership aims to leverage AI to drive innovation in drug development and improve patient outcomes. Boehringer Ingelheim and Microsoft will collaborate on research projects, including the use of digital twins to simulate clinical trials and optimize manufacturing processes. The partnership will also explore the application of AI in precision medicine and disease modeling.